VTVT Stock - vTv Therapeutics Inc.
Unlock GoAI Insights for VTVT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.02M | N/A | $2.02M | $4.00M | $6.41M |
| Gross Profit | $1.02M | N/A | $2.02M | $4.00M | $-4,601,000 |
| Gross Margin | 100.0% | N/A | 100.0% | 100.0% | -71.7% |
| Operating Income | $-24,180,000 | $-25,502,000 | $-22,540,000 | $-21,662,000 | $-11,852,000 |
| Net Income | $-18,462,000 | $-20,250,000 | $-19,164,000 | $-12,987,000 | $-8,499,000 |
| Net Margin | -1815.3% | N/A | -949.7% | -324.3% | -132.5% |
| EPS | $-3.20 | $-9.71 | $-9.98 | $-8.29 | $-7.21 |
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 19th 2025 | BTIG Research | Initiation | Buy | $40 |
Earnings History & Surprises
VTVTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.66 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.97 | $-1.08 | -11.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.85 | $-0.92 | -8.2% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.73 | $-0.77 | -5.5% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.87 | $-0.55 | +36.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-3.60 | $-0.88 | +75.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-3.20 | $-0.81 | +74.7% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-3.20 | $-1.17 | +63.4% | ✓ BEAT |
Q1 2024 | Mar 13, 2024 | $-2.80 | $-1.67 | +40.4% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-3.20 | $-3.20 | 0.0% | = MET |
Q3 2023 | Aug 11, 2023 | $-0.07 | $-2.80 | -3900.0% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-3.20 | $-2.40 | +25.0% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-2.40 | $-2.40 | 0.0% | = MET |
Q4 2022 | Nov 10, 2022 | $-2.00 | $-2.00 | 0.0% | = MET |
Q3 2022 | Aug 15, 2022 | $-4.00 | $-1.60 | +60.0% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-3.20 | $-4.00 | -25.0% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-3.20 | $-3.20 | 0.0% | = MET |
Q4 2021 | Nov 9, 2021 | $-2.80 | $-0.80 | +71.4% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-2.80 | $-0.40 | +85.7% | ✓ BEAT |
Latest News
HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Raises Price Target to $47
📈 PositivevTv Therapeutics And M42's IROS Submits Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health; This Study Constitutes The Longest Trial Investigating Cadisegliatin To Date
📈 PositiveBTIG Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $40
📈 PositivevTv Therapeutics Q3 EPS $(1.08) Misses $(0.98) Estimate
📉 NegativevTv Therapeutics announces $80M PIPE financing; shares up 14%
📈 PositivevTv Therapeutics Enters $80M PIPE Financing With Institutional Investors And The T1D Fund
📈 PositiveFrequently Asked Questions about VTVT
What is VTVT's current stock price?
What is the analyst price target for VTVT?
What sector is vTv Therapeutics Inc. in?
What is VTVT's market cap?
Does VTVT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VTVT for comparison